| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Sunday, April 26, 2020 7:56:21 AM
venus537....
Quote: "Publicly Amarin's plan is then to compete with the generics with their own generic Vascepa in the U.S. and have partnerships in Europe. That sounds like a nightmare within a nightmare."
Why so? The perfect is the enemy of the good. The market for Vascepa is going to be mind blowing...A fraction of Vascepa sales could be worth more than the whole pie of another drug...Amarin is going to have tied up a lot of the suppliers and very likely could have lower costs in producing the drug to the point where it is no longer profitable for the generics..I have always and still believe Vascepa will pretty much sell itself..Most people want to live longer..You can not look at the first couple of months of sales particularly when we are under quarantine.
Do we really need a partner in Europe...How bout using the Japanese model.Don't partner..Just open the dealerships employ the locals,,and have your people in charge of management..
The generics are not home yet..There is the very sticky subject of the fact Vascepa embodies a patented capsule which tends to retard the degradation of the EPA...Getting around those patents and complying with FDA requirements might lead to a couple of years or more delay or maybe the Generics will not get Judge Du in the next patent fight..
Keep your sunny side up...Pleasant dreams...
":>) JL
Quote: "Publicly Amarin's plan is then to compete with the generics with their own generic Vascepa in the U.S. and have partnerships in Europe. That sounds like a nightmare within a nightmare."
Why so? The perfect is the enemy of the good. The market for Vascepa is going to be mind blowing...A fraction of Vascepa sales could be worth more than the whole pie of another drug...Amarin is going to have tied up a lot of the suppliers and very likely could have lower costs in producing the drug to the point where it is no longer profitable for the generics..I have always and still believe Vascepa will pretty much sell itself..Most people want to live longer..You can not look at the first couple of months of sales particularly when we are under quarantine.
Do we really need a partner in Europe...How bout using the Japanese model.Don't partner..Just open the dealerships employ the locals,,and have your people in charge of management..
The generics are not home yet..There is the very sticky subject of the fact Vascepa embodies a patented capsule which tends to retard the degradation of the EPA...Getting around those patents and complying with FDA requirements might lead to a couple of years or more delay or maybe the Generics will not get Judge Du in the next patent fight..
Keep your sunny side up...Pleasant dreams...
":>) JL
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
